Wells Fargo & Company Kronos Bio, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 347 shares of KRON stock, worth $433. This represents 0.0% of its overall portfolio holdings.
Number of Shares
347
Previous 341
1.76%
Holding current value
$433
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding KRON
# of Institutions
60Shares Held
21.7MCall Options Held
4.8KPut Options Held
0-
Bvf Inc San Francisco, CA2.91MShares$3.63 Million0.11% of portfolio
-
Vida Ventures Advisors, LLC2.77MShares$3.46 Million5.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$2.44 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.83MShares$2.28 Million0.0% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.8 Million0.08% of portfolio
About Kronos Bio, Inc.
- Ticker KRON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,769,100
- Market Cap $71M
- Description
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...